Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 3/20 | 0.96 |
| ▸ | ACHE | P22303 | 1/20 | 0.96 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | PNP | P00491 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 2/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xanthine SCHEMBL2352524 | 0.98 | GDA (1.00) | GDAACHEABL1RIN1ADORA2B | |
| Xanthine SCHEMBL4965 | 0.98 | GDA (1.00) | GDAACHEABL1RIN1ADORA2B | |
| Xanthine SCHEMBL29669592 | 0.98 | GDA (1.00) | GDAACHEABL1RIN1ADORA2B | |
| Xanthine SCHEMBL7044227 | 0.96 | GDA (0.96) | GDAACHEABL1RIN1ADORA2B | |
| Xanthine SCHEMBL31152020 | 0.96 | GDA (0.96) | GDAACHEABL1RIN1ADORA2B | |
| Xanthine SCHEMBL6783299 | 0.96 | GDA (0.96) | GDAACHEABL1RIN1ADORA2B | |
| Xanthine SCHEMBL2454001 | 0.96 | GDA (0.96) | GDAACHEABL1RIN1ADORA2B | |
| Xanthine SCHEMBL7044230 | 0.96 | GDA (0.96) | GDAACHEABL1RIN1ADORA2B | |
| Xanthine SCHEMBL31488667 | 0.96 | GDA (0.96) | GDAACHEABL1RIN1ADORA2B | |
| Xanthine SCHEMBL7849418 | 0.96 | GDA (0.96) | GDAACHEABL1RIN1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 410 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119817601-A | Composite microbial agent and application thereof in improving saline-alkali stress resistance of crops | 山东农大肥业科技股份有限公司 | 2025-04-15 | — | — | CN | claimed |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION | 2023-09-14 | — | — | US | claimed |
| WO-2023039578-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION (US) | 2023-03-16 | — | — | WO | claimed |
| EP-3900712-A1 | GPCR HETEROMER INHIBITORS AND USES THEREOF | GPCR Therapeutics, Inc. (KR) | 2021-10-27 | — | — | EP | claimed |
| EP-3727371-A1 | GPCR HETEROMER INHIBITORS AND USES THEREOF | GPCR Therapeutics, Inc. (KR) | 2020-10-28 | — | — | EP | claimed |
| US-20190209594-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | UNIVERSITE PAUL SABATIER TOULOUSE III (FR) | 2019-07-11 | — | — | US | claimed |
| EP-3452092-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-03-13 | — | — | EP | claimed |
| WO-2017191300-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-11-09 | — | — | WO | claimed |
| EP-2507241-A1 | METHANOCARBA ADENOSINE DERIVATIVES AND DENDRIMER CONJUGATES THEREOF | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2012-10-10 | — | — | EP | claimed |
| US-20110189255-A1 | DRUG-ELUTING STENTS FOR ADENOSINE RECEPTOR MODULATION | PURDUE RESEARCH FOUNDATION | 2011-08-04 | — | — | US | claimed |
| EP-1014995-A1 | COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSIS FOLLOWING REVASCULARIZATION PROCEDURES | Discovery Therapeutics, Inc. (US) | 2000-07-05 | — | — | EP | claimed |
| US-6060481-A | Method for improving insulin sensitivity using an adenosine receptor antagonist | THE PENN STATE RESEARCH FOUNDATION (US) | 2000-05-09 | — | — | US | claimed |
| EP-0970696-A1 | Combination of loop diuretics with adenosine A1-receptor antagonists | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2000-01-12 | — | — | EP | claimed |
| EP-0814810-A4 | ADENOSINE AS A POSITIVE INOTROP IN THE COMPROMISED HEART | UNIV MASSACHUSETTS MEDICAL (US) | 1999-06-09 | — | — | EP | claimed |
| WO-1998057651-A1 | COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSIS FOLLOWING REVASCULARIZATION PROCEDURES | DISCOVERY THERAPEUTICS, INC. (US) | 1998-12-23 | — | — | WO | claimed |
| EP-0814810-A1 | ADENOSINE AS A POSITIVE INOTROP IN THE COMPROMISED HEART | UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER (US) | 1998-01-07 | — | — | EP | claimed |
| US-5629298-A | INCREASING CONTRACTILE PERFORMANCE, ADENOSINE TRANSPORT INHIBITORS USED AS POTENTIATORS | UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER (US) | 1997-05-13 | — | — | US | claimed |
| EP-0755254-A1 | PREVENTION AND TREATMENT OF ISCHEMIA-REPERFUSION AND ENDOTOXIN-RELATED INJURY USING ADENOSINE AND PURINO RECEPTOR ANTAGONISTS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1997-01-29 | — | — | EP | claimed |
| WO-1996028163-A1 | ADENOSINE AS A POSITIVE INOTROP IN THE COMPROMISED HEART | UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER (US) | 1996-09-19 | — | — | WO | claimed |
| WO-1995026728-A1 | PREVENTION AND TREATMENT OF ISCHEMIA-REPERFUSION AND ENDOTOXIN-RELATED INJURY USING ADENOSINE AND PURINO RECEPTOR ANTAGONISTS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1995-10-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | TP53, CD4, MCL1 | GDA 1187/4885ACHE 3357/4885ABL1 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.